Future directions in endometriosis treatment: discovery and development of novel inhibitors of estrogen biosynthesis

Fabio Barra, Andrea Romano, Giovanni Grandi, Fabio Facchinetti, Simone Ferrero
Expert opinion on investigational drugs · 2019 · vol. 28(6) , pp. 501–504 · doi:10.1080/13543784.2019.1618269 · PMID:31072144 · W2944325431
editorial OA: green CC0 ⤵ 9 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This paper explores novel inhibitors of estrogen biosynthesis enzymes, specifically AKR1C3, steroid sulphatase, 17β-HSD1, and aromatase, for future endometriosis treatment strategies.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

KEYWORDS: Endometriosisestrogen biosynthesisAKR1C3steroid sulphatase17β-hydroxysteroid dehydrogenase 1aromatase inhibitors

My notes (saved in your browser only)

Condition tags

mesh:D004715endometriosis

MeSH descriptors

Endometriosis Enzyme Inhibitors Estrogens Animals Aromatase Inhibitors Aromatase Inhibitors Drug Development Drug Development Drug Discovery Drug Discovery Endometriosis Endometriosis Enzyme Inhibitors Estrogens Female Humans

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (25)

Cited by (9)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:22:48.502547+00:00
License: CC0 · commercial use OK